Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM. Jonathan L. Kaufman, MD: The 3 IMiDs, or immunomodulatory drugs, we have ...
Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy ...
Multitargeted therapy using two biologics or one biologic combined with one JAK inhibitor showed effectiveness in select pediatric patients with refractory immune-mediated inflammatory diseases (IMIDs ...
Effect of carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma (RMM) by line of therapy: Secondary analysis from an ...
Protein degraders, which induce the protein degradation of target proteins, are expected to be the "next-generation drugs" because they can remove disease-related proteins from cells. Protein ...
Please provide your email address to receive an email when new articles are posted on . For pregnancies at 20 weeks of gestation or greater, many IMIDs were “only weakly associated” with risk for ...
Please provide your email address to receive an email when new articles are posted on . Patients with rheumatic immune-mediated inflammatory disease who experience myocardial infarction are more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results